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a  b  s  t  r  a  c  t
Background:  Inﬂammatory  reactions  and  oxidative  stress,  which  are  important  in  progression  of
atherosclerosis,  are  reported  to be  increased  in  individuals  with  metabolic  syndrome  (MetS).  On  the
other hand,  adiponectin  levels  are  lowered.  Since  effects  of  pitavastatin  on these  parameters  have  not
been  reported  in  hypercholesterolemic  patients  with  MetS,  the  present  study  was  conducted.
Purpose:  To  evaluate  the  effects  of  pitavastatin  on  inﬂammatory  reaction,  oxidative  stress,  and  plasma
adiponectin  levels  in  hypercholesterolemic  MetS  patients  in  a  multicenter  trial.
Methods:  This open-label,  single  group  study  was performed  at 7 hospitals  in  Japan.  Pitavastatin
(2  mg/day)  was administered  to 103  consecutive  patients  with  hypercholesterolemia,  subdivided  into
MetS  and  non-MetS  for  12 weeks.  Blood  samples  were  collected  after  overnight  fasting  at  the start  of
treatment  (baseline)  and  after  12  weeks.
Results:  In the  patients  with  MetS  (n = 69),  mean  values  of plasma  high-sensitivity  C-reactive  protein  (hs-
CRP)  were  signiﬁcantly  higher  and  mean  values  of plasma  high-molecular-weight  (HMW)-adiponectin
signiﬁcantly  lower  than  in  their  counterparts  without  MetS  (n  = 34).  The  baseline  HMW-adiponectin  and
high-density  lipoprotein  cholesterol  (HDL-C)  values  signiﬁcantly  correlated  only  in the  MetS  patients
(r =  0.318;  p  = 0.01).  In  an  effectiveness  analysis  including  94  patients  (62 with  MetS,  32  without  MetS),
the  level  of  hs-CRP  was  signiﬁcantly  decreased  in patients  with  MetS  during  the  drug  treatment,  whereas
HMW-adiponectin  did  not  change.  When  patients  with  MetS  were  divided  into  two  subgroups  according
to  the percent  changes  in  HDL-C,  signiﬁcantly  greater  increase  in  HMW-adiponectin  by  pitavastatin
treatment  was observed  in  the  HDL-C  ≥10%  increase  subgroup  than  in  the  HDL-C  <10%  increase  subgroup
(p =  0.009).
Conclusion:  Twelve  weeks  administration  of  pitavastatin,  in  addition  to the  antihyperlipidemic  effects,
may  be beneﬁcial  as  an anti-atherosclerotic  therapy  in hypercholesterolemic  patients  with  MetS,  taking
changes  in  hs-CRP  and  HMW-a
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ntroduction
The metabolic syndrome (MetS) is deﬁned as a cluster of car-
iovascular risk factors including visceral obesity, dyslipidemia,
levated blood pressure, and impaired glucose tolerance [1].  Epi-
emiologic studies have shown a clear link with cardiovascular
isease (CVD) [2,3], and inﬂammatory reaction and oxidative stress,
mportant in progression of atherosclerosis, may  be increased in
ndividuals with MetS [4–7]. High-sensitivity C-reactive protein
hs-CRP) is a useful low-grade inﬂammation marker and an impor-
ant risk factor for CVD [8],  which is also reported to be elevated in
etS cases [5].
Adiponectin is an adipose-derived plasma protein that is
ownregulated in subjects with obesity-related disorders [9–11],
ncluding MetS, and it is reported that low levels are associated with
ncreased risk of CVD [12,13]. Thus, this adipocyte protein could
e a key molecule for clarifying the pathogenesis of MetS-linked
isorders such as CVD.
Many clinical trials have shown that low-density lipoprotein
holesterol (LDL-C) reduction with HMG-CoA reductase inhibitors
statins) reduces coronary heart disease (CHD) morbidity and mor-
ality in hypercholesterolemic patients [14,15]. Statins also might
ave beneﬁcial pleiotropic effects such as anti-inﬂammatory and
nti-oxidative actions as well as in heart failure that are indepen-
ent of their cholesterol-lowering effects [16–18].  Pitavastatin has
otent LDL-C lowering and high-density lipoprotein cholesterol
HDL-C) elevating effects in clinical use [19], and has also demon-
trated anti-inﬂammatory and anti-oxidative effects in animal
tudies [20]. It was further found to increase plasma adiponectin
evels in patients with or without type 2 diabetes mellitus [21,22].
owever, the effects of pitavastatin on inﬂammatory parameters,
xidative stress, and plasma adiponectin levels in hypercholes-
erolemic patients with MetS have not been reported, to our
nowledge. In the present study, this question was  therefore eval-
ated in a multicenter trial.
aterials and methods
tudy population
Eligible participants were men  and women with hypercholes-
erolemia, deﬁned in this study by the Japan Atherosclerosis Society
uidelines for prevention of atherosclerotic CVDs [23] as follows:
1) total cholesterol (TC) ≥220 mg/dL; (2) LDL-C ≥140 mg/dL; (3)
C ≥180 mg/dL or LDL-C ≥100 mg/dL judged to need lipid-lowering
herapy. Exclusion criteria were as follows: (1) lipid-lowering drug
reatment (statins, ﬁbrates); (2) familial hypercholesterolemia; (3)
yclosporine treatment; (4) a past history of hypersensitivity to
tatins; (5) pregnancy, suspicion of pregnancy, or lactating status;
6) renal disorders, a serum creatinine level more than 2.0 mg/dL, or
ndergoing dialysis; and (7) ineligible for other reasons in the opin-
on of the investigators. Written informed consent was  obtained
rom all patients before the study, which was approved by the
thics committee at each hospital. The investigation was  conducted
n accordance with the ethical principles originating in or derived
rom the Declaration of Helsinki and in compliance with the Good
linical Practice guidelines.
esign
The multicenter, open-label, single arm study (Pitavastatin’s
ffects on REduction of inﬂammation and oxidative stress in
atients with MetabolIc  Syndrome Under Multicenter Study [PRE-
IUM Study]) was performed at 7 hospitals in Japan. Between April
007 and August 2008, 103 consecutive patients matched for entry
riteria were enrolled at these hospitals.diology 60 (2012) 389–394
Pitavastatin (2 mg/day) was administered for 12 weeks, with
blood samples collected after overnight fasting at the start of
treatment (baseline) and immediately after the end of treatment.
Concomitant use of agents with anti-oxidative action (vitamin
C, vitamin E, and probucol), anti-hypertensive drugs, and anti-
diabetic drugs was  allowed, but addition or changes of dosage were
prohibited.
Baseline values and changes in the following parameters were
compared in subgroups of patients with or without MetS. Thio-
barbituric acid reactive substances (TBARS) were measured using
the lipid peroxidation test [24], and hs-CRP was determined by an
immunonephelometric assay. Adiponectin exists in human plasma
as different oligomers:low-molecular-weight (LMW)  forms such
as trimers or hexamers and high-molecular-weight (HMW) forms.
Structure-function studies have revealed that the latter are sig-
niﬁcantly more bioactive [25]. Thus, HMW  forms of adiponectin
were measured. Because it has been reported that adiponectin is
related to metabolic risk factors, including body mass index (BMI),
plasma glucose, insulin, homeostasis model assessment for insulin
resistance (HOMA-IR), serum triglycerides (TG), as well as HDL-C
[4,26,27], we  evaluated correlations among their baseline values.
Soluble intercellular adhesion molecule-1 (sICAM-1) concentra-
tions were determined by enzyme-linked immunosorbent assay.
The value for glycated hemoglobin (Hb)A1c (National Glycohe-
moglobin Standardization Program: NGSP) was  indicated with 0.4%
added to HbA1c measured [28].
MetS was deﬁned following the criteria of an American Heart
Association/National Heart, Lung, and Blood Institute Scientiﬁc
Statement and those with 3 or more of the following being consid-
ered positive [1]:  (1) waist circumference ≥85 cm in men  or ≥80 cm
in women; (2) TG ≥150 mg/dL; (3) HDL-C <40 mg/dL in men and
<50 mg/dL in women; (4) blood pressure ≥130/≥85 mmHg; and (5)
fasting glucose ≥100 mg/dL. The cut-off values for waist circumfer-
ence were modiﬁed with the values used in Japanese populations
[29].
Safety was assessed from the incidence of adverse events and
abnormal laboratory data.
Statistical analysis
Statistical analyses were performed with JMP  (SAS Insti-
tute, Cary, NC, USA). Quantitative data are expressed as
means ± standard deviations. The mean values and frequencies
between with and without MetS were compared using a Student
unpaired t-test and a Chi-square analysis, respectively. Differences
in continuous variables between before and after the study were
compared using a Student paired t-test. In all tests, a value of
p < 0.05 was considered statistically signiﬁcant.
Results
Patient characteristics
One hundred and three consecutive hypercholesterolemic
patients matched for entry criteria were enrolled at the 7 hospitals.
Of these, 69 were diagnosed with MetS. Patient characteristics and
concomitant medication use are shown in Tables 1 and 2, respec-
tively. In MetS patients, mean values for BMI, waist circumference,
TG, fasting plasma glucose, hs-CRP, and sICAM-1 were signiﬁcantly
higher, and mean values for HDL-C and HMW-adiponectin were
signiﬁcantly lower than in patients without MetS. TBARS values
did not differ between the two groups.Effects of pitavastatin in hypercholesterolemic patients
Nine patients discontinued pitavastatin treatment before the
end of the 12-week period because of adverse events (dizziness,
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Table  1
Baseline clinical characteristics.
MetS (+) MetS (−) p
Age (years) 62.9 ± 11.2 63.0 ± 12.2 0.924
Number (men/women) 69 (36/33) 34 (19/15) 0.723
BMI  (kg/m2) 26.8 ± 3.7 23.6 ± 4.1 <0.001
Waist  circumference (cm) 92.0 ± 9.4 80.9 ± 11.2 <0.001
Coronary artery diseases (%)a 29 (42) 5 (15) 0.007
Stroke,  n (%) 4 (6) 1 (3) 0.545
Diabetes, n (%) 28 (41) 7 (21) 0.054
Hypertension, n (%) 46 (67) 12 (36) 0.004
Smoking, n (%) 12 (17) 5 (15) 0.776
Systolic blood pressure (mmHg) 135.5 ± 13.4 132.5 ± 17.1 0.334
Diastolic blood pressure (mmHg) 78.9 ± 10.2 75.0 ± 11.1 0.083
Total  cholesterol (mg/dL) 250.1 ± 42.8 253.3 ± 28.6 0.700
LDL-C  (mg/dL) 162.1 ± 34.5 159.8 ± 36.4 0.761
HDL-C  (mg/dL) 53.3 ± 16.8 62.4 ± 14.9 0.011
Triglycerides (mg/dL) 176.9 ± 121.3 115.8 ± 59.9 0.008
Fasting  plasma glucose (mg/dL) 114.3 ± 27.5 101.6 ± 24.1 0.028
Fasting  plasma insulin (U/mL) 13.0 ± 14.0 8.4 ± 13.7 0.150
HbA1c  (%) 6.15 ± 0.85 5.81 ± 0.65 0.052
HOMA-IR 3.85 ± 4.74 2.25 ± 3.94 0.136
hs-CRP  (mg/mL) 0.24 ± 0.33 0.07 ± 0.09 0.006
TBARS  (nmol/mL) 0.65 ± 0.40 0.66 ± 0.66 0.923
HMW-adiponectin (g/mL) 2.45 ± 2.06 3.96 ± 2.61 <0.002
sICAM-1 (ng/mL) 309.9 ± 109.8 268.1 ± 78.6 0.048
Data are presented as means ± standard deviations.

























cOMA-IR, homeostasis model assessment for insulin resistance; hs-CRP, high sensiti
igh-molecular-weight-adiponectin; sICAM-1, soluble intercellular adhesion molec
a Coronary artery diseases are deﬁned in terms of a history of myocardial infarcti
 = 2; musculoskeletal pain, n = 1; joint pain, n = 1; headache, n = 1;
ash, n = 1; and lip numbness, n = 1), and abnormal liver laboratory
ata (n = 2). These 9 patients were excluded from the effectiveness
nalysis, which thus covered 94 patients (62 with and 32 without
etS).
The level of hs-CRP was signiﬁcantly decreased after pitavas-
atin treatment in patients with MetS but not without MetS.
BARS, HMW-adiponectin, sICAM-1, and parameters of glucose
etabolism did not change after treatment in either group. The
evels of TC and LDL-C were signiﬁcantly decreased in both groups,
hile values for TG were signiﬁcantly decreased in MetS patients
ith a baseline value >150 mg/dL and for HDL-C were signiﬁcantly
ncreased in MetS patients with baseline values of men  <40 mg/dL
nd women <50 mg/dL (Table 3).
elationship between HMW-adiponectin and HDL-CFig. 1 shows a signiﬁcant correlation with the baseline HMW-
diponectin and the baseline HDL-C values in patients with MetS
r = 0.318; p = 0.011), but not without MetS (r = 0.252; p = 0.179).
hen patients with MetS were divided into two subgroups
able 2
oncomitant medication in study subjects.
MetS (+) MetS (−) p
ARB, n (%) 22 (32) 7 (21) 0.264
ACE  inhibitor, n (%) 6 (9) 2 (6) 0.643
Calcium-channel blockers, n (%) 30 (43) 6 (18) 0.012
Beta-blockers, n (%) 14 (20) 6 (18) 0.802
Diuretics, n (%) 12 (17) 4 (12) 0.494
Nitrates, n (%) 10 (14) 3 (9) 0.444
Aspirin, n (%) 21 (30) 5 (15) 0.096
Sulfonylurea, n (%) 6 (9) 1 (3) 0.290
Alfa-glucosidase inhibitors, n (%) 6 (9) 1 (3) 0.290
Thiazolidine, n (%) 4 (6) 1 (3) 0.545
ata are presented as means ± standard deviations.
etS, metabolic syndrome; ARB, angiotensin II receptor blocker; ACE, angiotensin-
onverting enzyme.reactive protein; TBARS, thiobarbituric acid reactive substance; HMW-adiponectin,
.
angina pectoris, or previous coronary revascularization.
according to the percentage change in HDL-C from baseline to
12-week pitavastatin treatment, it was  found HMW-adiponectin
increased by 18 ± 35% (p = 0.047) in response to pitavastatin treat-
ment in the HDL-C ≥10% increase subgroup, whereas it did
not change in the HDL-C <10% increase subgroup (−4 ± 27%,
p = 0.370). The difference between the percentage changes in
HMW-adiponectin in the HDL-C ≥10% and HDL-C <10% increase
subgroups was statistically signiﬁcant (p = 0.009, Fig. 2).
Discussion
The present study revealed a signiﬁcant correlation with
the baseline HMW-adiponectin and the baseline HDL-C val-
ues in hypercholesterolemic patients with MetS. Furthermore, it
was found HMW-adiponectin increased in response to 12-week
pitavastatin treatment only in the HDL-C ≥10% increase subgroup.
In the investigation, hs-CRP, a marker of inﬂammation, and sICAM-
1, the circulating form of ICAM-1 which mediates attachment
of circulating leukocytes to endothelium and their subsequent
transmigration and accumulation in the arterial intima [30], were
elevated in hypercholesterolemic patients with MetS, in line with
previous reports [4,6]. The low HMW-adiponectin levels in these
patients were also compatible with previous reports [31].
Plasma adiponectin concentrations positively correlated with
HDL-C levels as previously reported [4,26,27]. It is widely known
that low HDL-C is an important risk factor for CHD [32]. Low lev-
els of adiponectin are also associated with increased prevalence
of obesity-linked CVD, including CHD [12,26], and experimental
studies have shown that adiponectin protects against develop-
ment of atherosclerosis [13]. Intra-abdominal fat areas and plasma
adiponectin correlate with HDL-C concentrations, possibly medi-
ated by effects of adiponectin on hepatic lipase activity, which
is increased in central obesity and insulin resistance states asso-
ciated with the MetS [27]. HDL plays a crucial role in removing
excess cholesterol for atherosclerotic plaques and transporting it
back to the liver in the protective, so-called reverse cholesterol
transport. Adiponectin might accelerate this transport system by
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wig. 1. Relationship of the baseline high-molecular-weight (HMW)-adiponectin an
pen  circles, MetS (−) patients]. MetS, metabolic syndrome.
ncreasing cellular cholesterol efﬂux from macrophages through
he ATP-binding cassette transporter pathway [33].
The present study did not demonstrate increased plasma HMW-
diponectin levels with pitavastatin treatment for 12 weeks in
ypercholesterolemic patients with MetS. In previous reports,
otal adiponectin levels increased after 6 months, but not 3
onths of treatment [21,22]. In addition, pravastatin treatment
or 6 months was shown to increase serum adiponectin con-
entrations in Japanese patients with CHD [34]. The period of
2 weeks might have been too short. However, elevation was
ere found only in the HDL-C ≥10% increase subgroup, suggest-
ng that increase of HDL-C in response to pitavastatin treatment
s causally related to increase in adiponectin. The precise mecha-
isms underlying the relation between the observed increases in
DL-C and HMW-adiponectin associated with pitavastatin treat-
ent remain unclear. Recent work has shown that HDL may
e atheroprotective through anti-inﬂammatory and anti-oxidative
ffects [35], inﬂammation being closely linked to oxidative stress
s well as hypoadiponectinemia [7].  Thus, increase in HDL-C
y pitavastatin treatment may  increase anti-inﬂammatory and
nti-oxidative effects, increasing HMW-adiponectin in hyper-
holesterolemic patients with MetS. Previously, 6 months of
reatment with pravastatin increased adiponectin in tandem with
DL-C [34]. The present results thus suggest that pitavastatin may
revent the development of atherosclerosis through inﬂuence on
able 3
ffects of 12-week administration of pitavastatin on lipids and biochemical parameters.
MetS (+) (n = 62) 
Baseline 12 weeks 
Total cholesterol (mg/mL) 250.8 ± 43.8 181.9 ± 29.5 
LDL-C (mg/dL) 162.7 ± 36.4 106.3 ± 24.6 
HDL-C (mg/dL) 53.3 ± 16.6 56.6 ± 15.4 
Low  HDL-C 38.1 ± 5.5 46.8 ± 10.1 
Triglyceride (mg/dL) 175.0 ± 127.8 144.2 ± 97.7 
>150  mg/dL 256.6 ± 142.3 183.6 ± 108.6 
Fasting plasma glucose (mg/dL) 115.0 ± 28.5 115.5 ± 29.5 
Fasting plasma insulin (U/mL) 13.4 ± 14.7 12.6 ± 14.4 
HbA1c (%) 6.18 ± 0.87 6.16 ± 0.95 
HOMA-IR 3.92 ± 4.92 3.51 ± 4.22 
hs-CRP (mg/mL) 0.26 ± 0.34 0.14 ± 0.15 
TBARS (nmol/mL) 0.66 ± 0.42 0.66 ± 0.25 
HMW-adiponectin (g/mL) 2.45 ± 2.07 2.46 ± 1.71 
sICAM-1 (ng/mL) 308.0 ± 114.8 312.7 ± 127.8 
ata are presented as means ± standard deviations.
etS, metabolic syndrome; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-densi
odel  assessment for insulin resistance; hs-CRP, high sensitivity C-reactive protein; TB
eight-adiponectin; sICAM-1, soluble intercellular adhesion molecule-1.metabolic syndrome positive patient subgroups deﬁned according to the change
in high-density lipoprotein cholesterol (HDL-C) during pitavastatin treatment of 12
weeks.
HDL-C with HMW-adiponectin, in addition to lowering lipids in
hypercholesterolemic patients with MetS.
The present study also demonstrated that 12 weeks of pitavas-
tatin treatment decreased TC and LDL-C in hypercholesterolemic
patients with MetS. A decrease in TG among MetS patients with
MetS (−) (n = 32)
p Baseline 12 weeks p
<0.001 257.1 ± 29.0 181.7 ± 24.0 <0.001
<0.001 160.4 ± 35.7 98.3 ± 20.9 <0.001
0.266 63.8 ± 15.8 67.3 ± 18.1 0.427
0.003
0.138 126.5 ± 64.1 101.1 ± 74.9 0.157
0.038
0.929 101.3 ± 24.8 103.8 ± 22.5 0.687
0.784 8.8 ± 14.1 10.9 ± 13.2 0.589
0.855 5.74 ± 0.64 5.72 ± 0.54 0.905
0.667 2.39 ± 4.07 3.29 ± 4.98 0.483
0.031 0.08 ± 0.09 0.07 ± 0.13 0.900
0.902 0.64 ± 0.68 0.75 ± 0.44 0.491
0.965 3.89 ± 2.57 3.77 ± 2.58 0.844
0.841 268.6 ± 79.8 279.8 ± 81.9 0.585
ty lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis
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igher basal TG levels and an increase in HDL-C among those with
ower basal HDL-C levels were further shown. This improvement in
he lipid proﬁle was compatible with a recent report on pitavastatin
n Japanese subjects [19]. In addition to its lipid-lowering effects,
he present study demonstrated that pitavastatin lowered hs-CRP
n hypercholesterolemic patients with MetS whose basal hs-CRP
evels were higher than those without MetS. In cultured human
ndothelial cells, pitavastatin could be demonstrated to reduce
RNA levels of genes related to inﬂammation, such as interleukin-
 and monocyte chemoattractant protein-1 [36]. In addition, it
as reported that pitavastatin decreased hs-CRP in patients with
ypercholesterolemia, type II diabetes mellitus, and acute coronary
yndrome [37,38], independent of its lipid-lowering effects. Thus,
itavastatin may  have direct anti-inﬂammatory effects in hyperc-
olesterolemic patients with MetS.
TBARS, an oxidative stress marker reﬂecting plasma malon-
ialdehyde (MDA) concentrations resulting from lipid or cell
hiobarbituric acid peroxidation, were not elevated in our study
ubjects with MetS. While an increase was reported in one pre-
ious study of patients with MetS [7],  more recently a lack of
ny increment in it was described, probably due to increased uric
cid, which reduces organic peroxy radicals to hydroperoxides,
lockading degradation to LMW  aldehydes, including MDA  [39].
n the present study, uric acid was signiﬁcantly (p = 0.04) elevated
n patients with MetS (n = 13, 6.2 ± 1.5 mg/dL) as compared to those
ithout MetS (n = 23, 5.1 ± 1.3 mg/dL), except in individuals taking
rugs to decrease uric acid (n = 3) and whose uric acid was  not mea-
ured (n = 64). Therefore, the lack of TBARS increment found here
ight be due to reduced formation of MDA  by uric acid.
No serious adverse events were encountered in our study and
here were no abnormal laboratory data, for example in any param-
ters of glucose metabolism such as plasma glucose, HbA1c, and
OMA-IR. This is important, since atorvastatin and rosuvastatin
ave been reported to result in slight but signiﬁcant increase in
bA1c [40–42],  and it has been a matter of recent concern whether
tatins might cause a deterioration of glycemic control.
In conclusion, pitavastatin decreased hs-CRP levels in study sub-
ects with MetS, and increased HMW-adiponectin in the HDL-C
10% subgroup of the present PREMIUM study, without adverse
nﬂuence on glycemic control. These results suggest that this, in
ddition to the antihyperlipidemic effects, may  be beneﬁcial as an
nti-atherosclerotic therapy in hypercholesterolemic patients with
etS.
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